- Home
- KALV
KALV
KalVista Pharmaceuticals Inc.
as 11-20-2024 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $29.00 | AVG Volume (30 days): | 396.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.39 - $16.88 | Next Earning Date: | 12-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 179.39% |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Nov 17 '24 | Sell | $9.26 | 14,400 | $133,293.60 | 266,598 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Nov 17 '24 | Sell | $9.26 | 7,192 | $66,572.75 | 89,980 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Nov 17 '24 | Sell | $9.26 | 8,077 | $74,765.56 | 94,199 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Sep 6 '24 | Sell | $12.19 | 7,352 | $89,621.62 | 266,598 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
Business Wire
9 days ago
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
TipRanks
16 days ago
KalVista Secures $184M Financing for Sebetralstat Launch
Business Wire
16 days ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
17 days ago
KalVista Closes Royalty Financing Deal with DRI Healthcare, Prices $55 Million Offering
MT Newswires
17 days ago
DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat
Business Wire
17 days ago
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
Business Wire
17 days ago
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
Business Wire
24 days ago
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.